Evaluating kidney function in critically ill patients using iohexol
Evaluation of Glomerular Filtration Rate Using Iohexol Plasma Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance
This study is testing if a special dye called iohexol can give a more accurate picture of kidney function in critically ill patients compared to standard methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, Ile De France) |
| Trial ID | NCT04776486 on ClinicalTrials.gov |
What this trial studies
This study evaluates the glomerular filtration rate (GFR) in critically ill patients with augmented renal clearance by comparing measurements obtained through iohexol plasma clearance and creatinine clearance. It is a single-center study conducted in an intensive care unit (ICU) setting. The primary objective is to assess the accuracy of GFR estimates using iohexol as the reference method, while secondary objectives include comparing iohexol measurements with commonly used renal clearance estimating formulas and identifying clinical determinants of observed differences. The study aims to enhance understanding of kidney function in critically ill patients.
Who should consider this trial
Good fit: Ideal candidates for this study are ICU patients with a creatinine clearance greater than 130 ml/min/1.73m2.
Not a fit: Patients who are pregnant, have allergies to contrast media, or have undergone a CT scan with contrast on the day of inclusion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of kidney function assessments in critically ill patients, leading to better management and treatment decisions.
How similar studies have performed: Other studies have shown success in using iohexol for GFR measurement, indicating that this approach is established and has potential for further validation in this specific patient population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ICU patient * 24h Creatinine clearance \>130ml/min/1.73m2 * Urinary catheterization * Affiliation to a social security scheme Exclusion Criteria: * Pregnancy * CT-scan with contrast media infusion the day of inclusion * Documented allergy to contrast media * Patient under guardianship / curatorship * Patient benefiting from the "State Medical Assistance"
Where this trial is running
Paris, Ile De France
- Lariboisière Hospital, Surgical ICU — Paris, Ile De France, France (Recruiting)
Study contacts
- Principal investigator: Benjamin G Chousterman, MD PhD — Lariboisière Hospital, APHP Nord
- Study coordinator: Magalie Collet, MD
- Email: magalie.collet@aphp.fr
- Phone: +33 (0)149958515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.